|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Insmed Incorporated
| | | Phone: | (908) 977-9900 | Year Established: | 1999 | Employees: | 55 | Ticker: | INSM | Exchange: | NASDAQ | Main Contact: | Will Lewis, President & CEO | | Other Contacts: | Roger Adsett, CCO Eugene Sullivan, M.D., Chief Product Strategy Officer Paul Streck, M.D., CMO Paolo Tombesi, CFO Walter Perkins, Ph.D., CTO Christine Pellizzari, General Counsel & Corporate Secretary Eugene Sullivan, M.D., CSO
| | Company Description | Insmed is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company believes may offer a differentiated product profile with therapeutic potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), sarcoidosis, and severe refractory asthma. To complement its internal research, Insmed actively seeks in-licensing opportunities for a broad range of rare diseases. | |
|
|
|
|
|